Precision Dose Recalls Ranitidine Oral Solution Due to NDMA Impurity
Precision Dose Inc. is recalling Ranitidine Oral Solution because the active ingredient contained the impurity N-nitrosodimethylamine (NDMA).
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls with significant injury reports or structural defects are Severe; while no specific injuries are listed, the presence of NDMA, a known carcinogen, in a Class II drug recall aligns with the Severe tier for significant potential harm.
Plain-English summary
Precision Dose Inc. is recalling Ranitidine Oral Solution, USP, 150 mg/10 mL, in unit dose cups. The recall involves 224,940 unit dose cups distributed nationwide in the United States. The specific NDCs affected are 68094-204-61, 68094-204-62, and 68094-204-59.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the impurity N-nitrosodimethylamine (NDMA) was found in the active pharmaceutical ingredient (API). The affected lots include 501290, 501326, 501501, 1592, and 501679, with expiration dates ranging from November 30, 2019, to April 30, 2020.
This is a prescription-only medication. Patients and healthcare providers should stop using the recalled product and contact their healthcare provider for guidance on alternative treatments or replacements. The recall is classified as FDA Class II, indicating a reasonable probability that use of the product could cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Ranitidine Oral Solution, USP, 150 mg/10 mL, [10 mL x 30 Unit Dose Cups per case, NDC: 68094-204-62; 10 mL x 100 Unit Dose Cups per case, NDC: 68094-204-61; Unit Dose Cup NDC: 68094-204-59], Rx only, Precision Dose, Inc., South Beloit, IL 61080
- Manufacturer
- Precision Dose Inc.
- Category
- Drug — Oral Solution
- Affected units
- 224,940
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot number: 501290
- Expiry: 11/30/19
- NDC: 68094-204-61
- Lot number: 501326
- NDC: 68094-204-62
- Lot number: 501501
- Lot number: 1592
- Expiry: 4/30/20
- Lot number: 501679
- 68094-204-62
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Precision Dose Inc.
See all →- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateAcetaminophen Oral Suspension Recalled Due to Contaminated Raw Ingredient
FDA (Drugs) · 2021-11-17
- ModerateAcetaminophen Oral Suspension Recalled Due to Contaminated Raw Ingredient
FDA (Drugs) · 2021-11-17
- ModeratePrecision Dose Recalls Chlorhexidine Gluconate Oral Rinse Due to cGMP Deviations
FDA (Drugs) · 2021-01-20
- ModeratePrecision Dose Recalls Subpotent Carbamazepine Oral Suspension Unit Dose Cups
FDA (Drugs) · 2017-11-08
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11